Semax Research Guide: ACTH(4-10) Analog & BDNF Pathways

What Is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It is an analog of the N-terminal (4-10) fragment of adrenocorticotropic hormone (ACTH/corticotropin). The biologically active "core" is the ACTH(4-7) tetrapeptide Met-Glu-His-Phe; Semax appends a C-terminal Pro-Gly-Pro (PGP) tripeptide that confers resistance to enzymatic (carboxypeptidase) cleavage. For that reason the published literature describes it interchangeably as an ACTH(4-10) analog and as ACTH(4-7)PGP — it is not the full native ACTH(4-10) peptide, but a stabilized analog built on its active core.

Semax was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences and Lomonosov Moscow State University, and it anchors an extensive Russian neuropeptide research literature. Importantly, unlike its parent ACTH, Semax is devoid of corticotropic (cortisol-stimulating) hormonal activity in published studies while retaining the neurotropic activity derived from the melanocortin fragment. In rodent work it is typically administered intranasally (for example, 50 µg/kg), exploiting olfactory and trigeminal nose-to-brain transport.

Mechanism of Action: What the Research Shows

The primary documented mechanism of Semax in the literature is upregulation of neurotrophic factors and their receptors. Unlike a single-target receptor agonist, the reported activity centers on shifting the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) and their downstream signaling.

BDNF / TrkB Signaling

In rodent studies, a single intranasal dose increases BDNF protein and TrkB phosphorylation in the hippocampus and basal forebrain, with corresponding increases in exon-III BDNF and TrkB mRNA (Dolotov et al., 2006; Agapova et al., 2007). Radiolabeled [³H]Semax shows specific, saturable, reversible, Ca²⁺-dependent binding to rat basal-forebrain plasma membranes (K_d ~2.4 nM; B_max ~33.5 fmol/mg protein), indicating a discrete binding-site interaction rather than purely nonspecific action (Dolotov et al., 2006).

Region- and Gene-Specific Neurotrophin Regulation

The neurotrophin response is not a uniform brain-wide effect. BDNF and NGF responses differ by region — in animal models BDNF rose in hippocampus, brainstem and cerebellum, while NGF fell in frontal cortex (Agapova et al., 2007). This regional specificity is an important detail for research design, because it argues against treating Semax as a simple global neurotrophin "booster."

Monoaminergic Modulation

Semax also activates dopaminergic and serotonergic systems in rodents, with increased striatal 5-HIAA and altered dopamine/serotonin turnover (Eremin et al., 2005) — a neurochemical basis sometimes invoked for the behavioral and nootropic readouts reported in the literature.

Melanocortin Lineage and Pharmacokinetics

As an ACTH/melanocortin-fragment analog, Semax's activity is linked to melanocortin signaling (the literature notes melanocortin-4-receptor involvement), although the receptor-level mechanism is less fully characterized than the neurotrophin data. Pharmacokinetically, Semax is rapidly degraded by dipeptidyl-peptidase and other peptidases; the C-terminal Pro-Gly-Pro tripeptide is the predominant — and itself bioactive — metabolite. That rapid-degradation profile is precisely what motivated the PGP stabilization strategy and the development of stabilized variants such as N-acetyl Semax.

What the Research Literature Reports

The evidence base for Semax is mixed and largely preclinical. The strongest, best-replicated findings are mechanistic rodent and in vitro work; the human/clinical data is weaker by Western evidence standards. The findings below describe what the published literature has reported in its original study models and populations; none of it is presented as a use indication for research-grade material.

BDNF and TrkB Induction (the core mechanistic finding)

A single intranasal dose of Semax (50 µg/kg) raised BDNF protein ~1.4-fold and TrkB tyrosine-phosphorylation ~1.6-fold in rat hippocampus, with roughly 3-fold exon-III BDNF mRNA and 2-fold TrkB mRNA increases (Dolotov et al., Journal of Neurochemistry, 2006). A companion analysis reported that [³H]Semax binds specifically, reversibly and Ca²⁺-dependently to rat basal-forebrain plasma membranes (K_d 2.4 ± 1.0 nM; B_max 33.5 ± 7.9 fmol/mg), and that intranasal Semax (50 and 250 µg/kg) rapidly increased BDNF protein in basal forebrain — but not cerebellum — within 3 hours.

Region-Specific Neurotrophin Changes

Intranasal Semax produced rapid, region- and gene-specific neurotrophin changes: BDNF up in hippocampus, brainstem and cerebellum; NGF up in hippocampus but down in frontal cortex (Agapova et al., Neuroscience Letters, 2007). This is one of the clearest demonstrations in the literature that the effect is not a uniform upregulation.

Monoaminergic Activation

Semax activated monoaminergic systems in rodents: striatal 5-HIAA rose ~25% at 2 hours after dosing and extracellular 5-HIAA increased up to ~180% over 1–4 hours, with effects on dopaminergic turnover (Eremin et al., Neurochemical Research, 2005).

Neuroprotection in Ischemia Models

Genome-wide transcriptional analysis after permanent middle-cerebral-artery occlusion found Semax most strongly affected immune-response genes (more than half of altered genes at 24 hours; immunoglobulin/chemokine upregulation) plus vascular/angiogenesis genes — implicating immunomodulation and vascular remodeling, alongside neurotrophin induction, in its reported neuroprotective profile (Medvedeva et al., BMC Genomics, 2014).

The Human / Clinical Picture

Human evidence exists but is much weaker for international evidence standards: it is concentrated in Russian-language journals, often small, and frequently non-blinded or non-placebo-controlled. In a Russian-language rehabilitation study of 110 ischemic-stroke patients, Semax (alongside early rehabilitation) was reported to raise plasma BDNF and accelerate functional recovery on the Barthel index versus controls (Gusev et al., Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018). Earlier Russian work documented Semax-associated changes in the human electroencephalogram as part of the cognitive research base (Koroleva et al., Bulletin of Experimental Biology and Medicine, 1996).

Reconstitution & Handling for Research

Semax is supplied as a lyophilized (freeze-dried) white powder and is highly water-soluble. The notes below are general RUO laboratory-handling principles drawn from peptide-research practice and the degradation literature — they are not human-use instructions:

• Store cold and dark. Keep the lyophilized powder protected from light (commonly −20 °C for long-term storage; short-term refrigeration is acceptable) and avoid repeated freeze-thaw cycles.
• Reconstitute in aqueous diluent. For in vitro and preclinical work, Semax dissolves readily in bacteriostatic or sterile water and aqueous buffer; handle aseptically, avoid vortexing or foaming, and do not expose to high heat.
• Use solutions promptly. Because Semax is rapidly degraded by peptidases (notably dipeptidyl-peptidase; in vitro reports describe extensive degradation), reconstituted solutions are kept refrigerated and used within a limited window. The main breakdown product is the C-terminal Pro-Gly-Pro tripeptide, which is itself bioactive — the practical reason stabilized analogs (N-acetyl Semax, PGP-extended variants) exist.

A clear, particulate-free solution after gentle mixing indicates a clean preparation. Always verify handling against the specific Certificate of Analysis (COA) for your lot. None of this is a substitute for human-use directions, which are out of scope for research-grade material.

Semax vs Selank

Semax is frequently discussed alongside Selank, and the two share a real family resemblance — but they are not the same molecule and they are not studied for the same things. The honest summary is: same structural strategy, different origin peptide, different dominant pharmacology.

What They Share

• Both are synthetic heptapeptides from the same Russian research program (Institute of Molecular Genetics, RAS).
• Both end in a stabilizing C-terminal Pro-Gly-Pro (PGP) tail that slows enzymatic degradation.
• Both are typically studied intranasally, and both have some overlapping reported effects on BDNF and monoamines.

How They Differ

• Semax is an ACTH(4-10) analog (Met-Glu-His-Phe-Pro-Gly-Pro) of melanocortin / ACTH lineage. Its research leans toward cognition, neurotrophic-factor (BDNF/NGF) upregulation, monoaminergic activation, and neuroprotection in ischemia models.
• Selank is an analog of the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg, a fragment of the IgG heavy chain), with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its research leans toward anxiolytic effects, GABAergic-system modulation (altered GABA-A receptor-subunit gene expression; allosteric modulation rather than direct benzodiazepine-site binding — Volkova et al., Frontiers in Pharmacology, 2016), and immunomodulation.

So the precise difference to keep straight: same PGP-stabilization strategy and structural family, but a different origin peptide (ACTH/melanocortin for Semax vs tuftsin/IgG for Selank) and a different dominant pharmacology (Semax cognition/neurotrophic-leaning; Selank anxiolytic/GABAergic-leaning). Selank is referenced here for context only.

Evaluating Research-Grade Semax Supply

For reproducible work on neurotrophic and monoaminergic pathways, the supply chain matters as much as the compound. When sourcing Semax for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For a short heptapeptide like Semax, the COA should report:

• HPLC purity — the chromatogram that tells you how much of the vial is the intended peptide versus process-related impurities.
• Mass-spec confirmation — verifying the measured mass matches the expected Met-Glu-His-Phe-Pro-Gly-Pro heptapeptide, which is how you confirm you received the correct sequence and not a truncated or mislabeled peptide.
• Batch / lot number and a recent test date linking the COA to your specific vial.

Elytra Labs publishes batch-specific third-party COAs for the research peptides we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret the chromatogram and mass-spec data. Purity and identity claims should always come from the real COA for your lot, never from a general fact sheet.

2. Lyophilized Form and Cold-Chain Discipline

Semax should arrive as a lyophilized powder. Keep it cold, sealed and shielded from light until reconstitution, and reconstitute with clean bacteriostatic or sterile water. Because the peptide is rapidly degraded once in solution, a vendor that ships it properly and documents handling guidance is doing real quality control, not just shipping powder.

Frequently Asked Research Questions

What is Semax?

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, an analog of the ACTH(4-10) fragment of adrenocorticotropic hormone. The C-terminal Pro-Gly-Pro is added to slow enzymatic degradation, so it is described in the literature both as an ACTH(4-10) analog and as ACTH(4-7)PGP. It was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences.

What does the research say Semax does mechanistically?

In rodent studies, a single intranasal dose increased BDNF protein and TrkB-receptor signaling in the hippocampus and basal forebrain, with matching increases in BDNF and TrkB mRNA (Dolotov et al., 2006; Agapova et al., 2007). Radiolabeled Semax shows specific, saturable, reversible binding to rat basal-forebrain membranes with a dissociation constant around 2.4 nM (Dolotov et al., 2006). It also activates dopaminergic and serotonergic systems in rodents (Eremin et al., 2005). These are reported preclinical findings, not therapeutic claims.

Does Semax have hormonal (cortisol) activity like ACTH?

No. Unlike its parent ACTH, Semax has no corticotropic (cortisol-stimulating) hormonal activity in published studies. Its research interest is neurotropic, not hormonal — that loss of hormonal activity is one of the defining features of the analog.

How do Semax and Selank differ?

Both are Russian PGP-stabilized heptapeptides studied intranasally, but they derive from different parent peptides. Semax derives from ACTH and is studied for cognition and neurotrophic (BDNF/NGF) effects, whereas Selank derives from the immune peptide tuftsin and is studied for anxiolytic and GABAergic effects. Same structural family and stabilization strategy, different origin and different dominant pharmacology.

What does "research-grade" mean, and is Semax FDA-approved?

"Research-grade" indicates the peptide is intended for laboratory in vitro and animal-model investigation, synthesized in an appropriate facility, and accompanied by analytical documentation (purity, mass spec, batch records). It is not pharmaceutical- or human-grade. Semax is approved/registered in Russia but is not FDA-approved and lacks large international randomized controlled trials; it is not approved for human or veterinary therapeutic use in this context.